Holen Sie sich die Stockscreener-App
0.90
24.17%
0.1752
Schlusskurs vom Vortag:
$0.7248
Offen:
$0.74
24-Stunden-Volumen:
3.09M
Relative Volume:
2.02
Marktkapitalisierung:
$45.24M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-0.5056
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
+66.67%
1M Leistung:
+17.36%
6M Leistung:
-74.29%
1J Leistung:
-75.81%
1-Tages-Spanne:
$0.74
$0.9005
1-Wochen-Bereich:
$0.5231
$0.9005
52-Wochen-Spanne:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie STRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.90 | 45.24M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
LPL Financial LLC Has $667,000 Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Inc (STRO) gets rating Downgrade from H.C. Wainwright - knoxdaily.com
Anchoring Your Portfolio: Is STRO Stock a Safe Harbor? - investchronicle.com
Take off with Sutro Biopharma Inc (STRO): Get ready for trading - Sete News
Sutro Biopharma Inc (NASDAQ: STRO) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet - simplywall.st
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.54 amid market challenges - Investing.com Canada
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Holdings Boosted by American Century Companies Inc. - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sutro Biopharma announces board member departure By Investing.com - Investing.com Canada
Sutro Biopharma announces board member departure - Investing.com Australia
Sei Investments Co. Takes Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Changing FacesPharma and Biotech HiresMarch 2025 - pharmaphorum
Prudential Financial Inc. Increases Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Thrivent Financial for Lutherans Acquires Shares of 97,096 Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges - Investing.com
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Biotech company based in Peninsula laying off 90% of staff - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright - Investing.com Australia
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
21.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):